Zydus Lifesciences Ltd

Large Cap

Healthcare Sector

reflects a positive outlook for the share price

reflects a neutral outlook for the share price

reflects a negative outlook for the share price

The analysts information is for reference only and does not\n  represents an investment recommendation.

Analyst recommendation reflect the views of analysts who follow and write research reports.

Company Information is an introduction to the company’s business that details what it sell, how it was founded, what their mission is, how they manufacture or source their products, and why they serve customers.

Zydus Lifesciences shares increased by 1% following the receipt of the Establishment Inspection Report from the USFDA for its Ankleshwar facility, classified as No Action Indicated. The company also made a strategic entry into the global biologics CDMO market and received tentative approval for Rifaximin Tablets for IBS-D treatment.

Zydus Lifesciences Gains After USFDA Inspection Approval - 12 Jun, 2025

Zydus Lifesciences announced receipt of the Establishment Inspection Report from the USFDA for its Ankleshwar API facility, classified as No Action Indicated, ensuring compliance and operational continuity.

Zydus Lifesciences Receives Positive FDA Inspection Report - 11 Jun, 2025

Zydus Lifesciences received the USFDA's Establishment Inspection Report for its Dabhasa facility, classified as VAI. The company reported a slight decline in Q4 FY25 net profit, while revenue increased significantly. Shares rose for the fifth consecutive session.

Zydus Lifesciences Receives USFDA EIR and Reports Earnings - 10 Jun, 2025

Zydus Lifesciences demonstrates strong financial performance with strategic acquisitions and R&D investments. Key metrics indicate a buy recommendation at ₹955, targeting ₹1,080 in three months.

Zydus Lifesciences Shows Strong Financial Outlook - 06 Jun, 2025

Zydus Lifesciences is making significant moves by acquiring Agenus biologics facilities, reporting strong quarterly performance, and gaining favorable court rulings on patents. However, concerns about future US sales and margin pressures persist.

Zydus Lifesciences Expands Biologics and Patent Strategies - 05 Jun, 2025

Zydus Lifesciences is significantly enhancing its position in the global biologics market by acquiring two manufacturing facilities from Agenus and securing commercial rights for immuno-oncology therapies in India and Sri Lanka. The company also acquired a stake in Agenus, further solidifying its strategic focus on biologics as a growth driver.

Zydus Expands Biologics Footprint with Agenus Acquisitions - 03 Jun, 2025

Zydus Lifesciences has received tentative approval from the USFDA for Rifaximin Tablets, 550 mg, indicated for irritable bowel syndrome with diarrhea, with significant annual sales potential.

Zydus Lifesciences Secures USFDA Approval for Rifaximin - 02 Jun, 2025

Zydus Lifesciences stock closed at a two-month high after breaking a falling trendline. The stock has shown repeated higher lows, indicating potential for further gains towards its 200 DMA near 980.

Zydus Lifesciences Hits Two-Month High - 29 May, 2025

Zydus Lifesciences' stock reaches a two-month high following the USFDA's fast track designation for Usnoflast, a treatment for ALS, emphasizing the urgent need for effective therapies.

Zydus Lifesciences Gains Fast Track for ALS Drug - 28 May, 2025

Zydus Lifesciences has launched 'The Easiest Exam' campaign to promote self-breast examination for early breast cancer detection, reaching millions and gaining significant media attention.

Zydus Launches Impactful Breast Cancer Awareness Campaign - 27 May, 2025

Zydus Lifesciences has received FDA approval for its isotretinoin capsules, a generic version of Absorica, for treating severe acne. This approval enhances Zydus's dermatological portfolio and reflects its commitment to expanding in key markets.

Zydus Receives FDA Approval for Acne Drug - 23 May, 2025

Zydus Lifesciences showcases strong Q4 results with a 34% net profit increase. The company plans to expand its vaccines and medtech portfolio, targeting double-digit growth in FY26. Analysts maintain a mix of ratings, with some optimistic about future performance despite concerns over margin pressures and product concentration.

Zydus Lifesciences Reports Strong Growth and Future Plans - 21 May, 2025

Zydus Lifesciences targets double-digit revenue growth for FY26, despite a dip in Q4 profit to ₹1,244 crore. The company declares a final dividend of ₹11 per share, pending AGM approval. Overall, strong performance in US and India markets supports growth outlook.

Zydus Lifesciences Reports Q4 Results and FY26 Outlook - 20 May, 2025

Zydus Lifesciences announced receipt of the Establishment Inspection Report (EIR) from USFDA for its Ambernath API manufacturing facility, with no observations and classified as No Action Indicated (NAI).

Zydus Lifesciences Receives Favorable USFDA Inspection Report - 14 May, 2025

Price to Earnings Ratio or Price to Earnings Multiple is the ratio of the share price of a stock to its earnings per share (EPS). It provides an indication of whether a stock at its current market price is expensive or cheap.

The price/earnings-to-growth ratio, or the PEG ratio, is a metric that helps investors value a stock by taking into account a company's market price, its earnings, and its future growth prospects.

Enterprise value (EV) is the total value of a company, defined in terms of its financing. It includes both the current share price (market capitalization) and the cost to pay off debt (net debt, or debt minus cash).

Alpha measures the amount that the investment has returned in comparison to the market index or other broad benchmark that it is compared against.

Beta measures a stock's volatility, the degree to which its price fluctuates in relation to the overall stock market. In other words, it gives a sense of the stock's risk compared to that of the greater market.

Dividend yield measures the quantum of earnings by way of total dividends that investors make by investing in that company.

The debt-to-total-assets ratio shows how much of a business is owned by creditors (people it has borrowed money from) compared with how much of the company's assets are owned by shareholders.

Operating cash flow (OCF) is a measure of the amount of cash generated by a company's normal business operations. Operating cash flow indicates whether a company can generate sufficient positive cash flow to maintain and grow its operations.

This widget shows the information about the stock's peers in consideration along with the different data for those peers so that the user can compare the stock with the other similar stock and invest accordingly.

Promoter holding is the amount of share of the company that is owned by the promoters. The promoters are the company's founders, who hold a majority stake in the company's capital.

A foreign institutional investor (FII) is an investor or investment fund investing in a country outside of the one in which it is registered or headquartered.

A mutual fund is a pool of money managed by a professional Fund Manager. It is a trust that collects money from a number of investors who share a common investment objective and invests the same in equities, bonds, money market instruments, and other securities.

Retail investors execute their trades through traditional or online brokerage firms or other types of investment accounts. Retail investors purchase securities for their own personal accounts and often trade in dramatically smaller amounts as compared to institutional investors.

This widget shows the bifurcation of stocks based on the percentage of stake with the different types of shareholders.

This widget will help value the stock based on the Price to Earning ratio of the stock and compare the valuation with the industry value and other similar stocks. It even shows the timeline of the valuation of the stock and its highest and lowest valuation over time.
A Time Series data is provided which compares the historical stock PE with Industry PE over the period of 5 years.

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

Mutual Funds have increased holdings from 6.32% to 6.36% in Mar 2025 quarter

This section gives you an insight into how the Mutual Funds Holding has changed for the stock over last few quarters.

MF Holding Up

Promoters have increased holdings from 74.98% to 74.99% in Mar 2025 quarter

This section gives you an insight into how the Promoter Holding has changed for the stock over the last few quarters.

Promoter Holding Up

In the last 3 years, ZYDUSLIFE has outperformed top 5 stocks with highest market-cap in Pharmaceuticals

This section gives you an insight into why this company has been the best in its industry for the last 3 years.

Best in 3 Years

Revenue is up for the last 3 quarters, 5.30K Cr → 6.60K Cr (in ₹), with an average increase of 9.9% per quarter

This section gives you an insight into how the revenue of the company has moved for the last few quarters.

Revenue Rich

Netprofit is up for the last 3 quarters, 911.2 Cr → 1.17K Cr (in ₹), with an average increase of 11.8% per quarter

This section gives you an insight into how the profit for the company has been for the last few quarters.

Profit Spike

In the last 1 year, Divis Laboratories Ltd has given 45.3% return, outperforming this stock by 57.4%

This section gives you an insight into how the peers have performed as compared to this company in the last 1 year.

Against Peers

Foreign Institutions have decreased holdings from 7.53% to 7.32% in Mar 2025 quarter

This section gives you an insight into how the FII Holding has changed for the stock over last few quarters.

FII Holding Down

Retail Investor have decreased holdings from 6.84% to 6.68% in Mar 2025 quarter

This section gives you an insight into how the Retail Investors Holding has changed for the stock over last few quarters.

Retail Holding Down

In the last 6 months, ZYDUSLIFE stock has moved down by -1.3%

This section gives you an insight into the price movement of the stock for the last few quarters.

Price Dip

NIFTY PHARMA

Nifty Next 50

Nifty100 Quality

S&P BSE Largecap

S&P BSE 250 LargeMidCap

NIFTY 100

BSE 200

Nifty 200

Nifty LargeMidcap 250

Nifty 500

Nifty Healthcare

S&P BSE Dividend Stability

Nifty100 Eq Weig

S&P BSE 150 MidCap

S&P BSE 400 MidSmallCap

BSE Healthcare

BSE 500

Parag Parikh Flexi Cap Direct Growth

Kotak Flexicap Fund Direct Growth

ICICI Prudential Bluechip Fund Direct Plan Growth

ICICI Prudential Value Discovery Fund Direct Plan Growth

ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Direct Growth

Zydus Lifesciences Ltd’s net profit fell -0.96% since last year same period to ₹1,170.90Cr in the Q4 2024-2025. On a quarterly growth basis, Zydus Lifesciences Ltd has generated 14.4% jump in its net profits since last 3-months.

Name	Value	Action
MACD level (12,26)	-0.06	Bearish
CCI (20)	-390.1	Bullish
RSI (14)	43.56	Neutral
Momentum (10)	-1.45	Bearish
ADI (14)	24.49	Neutral
Ultimate Oscillator (7,14,28)	69.13	Neutral

Name	Value	Action
SMA (20)	974.98	Bearish
EMA (20)	974.61	Bearish
VWMA (20)	974.68	Bearish
SMA (50)	974.25	Bearish
EMA (50)	974.2	Bearish
SMA (200)	971.34	Bullish
EMA (200)	972	Bullish
KAMA (200)	973.55	Bullish
DEMA (200)	973.3	Bullish

Zydus Lifesciences Ltd (ZYDUSLIFE)

Summary

Overall

Oscillators

Moving Averages